Tudor Investment Corp Et Al Invests $901,000 in Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Christel Deskins

Tudor Investment Corp Et Al purchased a new position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 16,845 shares of the biopharmaceutical company’s stock, valued at approximately $901,000. Other institutional investors and hedge funds also recently added to or reduced their […]

Tudor Investment Corp Et Al purchased a new position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 16,845 shares of the biopharmaceutical company’s stock, valued at approximately $901,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. M&T Bank Corp acquired a new position in Agios Pharmaceuticals in the 1st quarter valued at approximately $10,644,000. Advisor Group Holdings Inc. raised its holdings in Agios Pharmaceuticals by 427.9% in the 2nd quarter. Advisor Group Holdings Inc. now owns 1,267 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 1,027 shares in the last quarter. Citizens Financial Group Inc RI raised its holdings in Agios Pharmaceuticals by 919.3% in the 2nd quarter. Citizens Financial Group Inc RI now owns 1,478 shares of the biopharmaceutical company’s stock valued at $79,000 after acquiring an additional 1,333 shares in the last quarter. Parallel Advisors LLC raised its holdings in Agios Pharmaceuticals by 1,510.3% in the 2nd quarter. Parallel Advisors LLC now owns 1,562 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,465 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Agios Pharmaceuticals by 1,186.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,672 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 1,542 shares in the last quarter. Institutional investors own 95.21% of the company’s stock.

Several equities analysts have commented on the company. Citigroup upped their price target on Agios Pharmaceuticals from $64.00 to $75.00 and gave the company a “buy” rating in a report on Monday, June 15th. BidaskClub raised Agios Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 1st. Needham & Company LLC initiated coverage on Agios Pharmaceuticals in a report on Thursday, July 30th. They issued a “buy” rating and a $71.00 price target for the company. ValuEngine cut Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd. Finally, Zacks Investment Research cut Agios Pharmaceuticals from a “buy” rating to a “hold” rating and set a $56.00 target price for the company. in a report on Tuesday, June 16th. One research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $68.77.

NASDAQ AGIO opened at $36.97 on Friday. The stock’s 50 day simple moving average is $42.62 and its 200 day simple moving average is $45.19. Agios Pharmaceuticals Inc has a one year low of $27.77 and a one year high of $56.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.36) by $0.05. The business had revenue of $37.30 million for the quarter, compared to the consensus estimate of $37.17 million. Agios Pharmaceuticals had a negative return on equity of 59.71% and a negative net margin of 182.49%. The firm’s revenue was up 42.4% compared to the same quarter last year. During the same quarter last year, the business posted ($1.87) EPS. Analysts forecast that Agios Pharmaceuticals Inc will post -4.58 earnings per share for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

See Also: The mechanics of the bid-ask spread in trading

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Agios Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Next Post

Innovation is more than a buzzword at one Navy center

Innovation doesn’t just happen at the Naval Surface Warfare Center Carderock Division. It’s something that people like Judy Conley and Jessica McElman promote, encourage and demonstrate. Conley, the science and technology coordinator for platform integrity, and McElman, the division head for underwater electromagnetic signatures and technology division at the Naval […]